Cooling adjunct for medications to treat disorders in the nasal cavity
US10722477B2 · kind B2 · utility
Inventor
Key dates
| Filing date | Mar 31, 2017 |
| Grant date | Jul 28, 2020 |
| Priority date | — |
| Expiry date | Mar 31, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61M2210/0618
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-alkyl-phosphinoyl-alkanes as described herein, DIPA-1-8 and DIPA-1-9, and 2-6 and 2-7 that are collectively referred to herein as “DAPA compounds”, that are useful in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by inflammation, irritation, itch, or pain) in the nasal cavity. The applicant has found that localized delivery of DAPA compounds in combination with an intranasal steroid or an intranasal antihistamine immediately relieves nasal discomfort and enhances patient adherence to the use of the nasal medications.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.